Table 3.

Tyrosine kinase inhibitors in clinical trials as anti-liver fibrosis agents.

TK inhibitors	ClinicalTrials.gov identifier	Recruited parcitipants	Intervention	Study phase	Status
Sorafenib	NCT01714609	Liver cirrhosis participants with portal hypertension	Sorafenib 400mg p.o. twice daily	Phase II	Completed
Erlotinib	NCT02273362	Liver cirrhosis participants following HCC resection	Erlotinib p.o. for 7 days	Phase I	Recruiting